Retrospective Study of the Association Between Platelet-to-Lymphocyte Ratio in Patients with Acute Coronary Syndrome on Admission to a Rural Referral Center in East Java, Indonesia, and the Incidence of New Symptomatic Heart Failure at 6 Months

Intan, Ryan Enast; Alkaff, Firas Farisi; Oktaviono, Yudi Her; Nugraha, Ricardo Adrian; Octora, Tan Nicko; Jonatan, Michael; Balti, Dimas Rio; Hasibuan, Fani Suslina; Radi, Basuni; Santoso, Anwar

doi:10.12659/msm.935002

Cited by 8 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The predictive power of increased PLR for HF complicating acute coronary syndromes was confirmed in a smaller cohort of 92 patients by Intan et al Patients with PLR > 108 on initial admission had an odds ratio of 1.70 (95%CI 1.33 -2.18, p < 0.001) of developing HF during a 6-months follow-up period [31]. In multivariable analysis adjusting, among others, for age, sex, kidney function, and LV ejection fraction, PLR remained an independent predictor for HF, with each unit increase in PLR associating an OR of 1.072 (95%CI 1.03 -1.11, p < 0.001) [31].…”

Section: Relationship With Coronary Artery Disease and The Risk Of De...mentioning

confidence: 82%

The platelet to lymphocyte ratio in heart failure: a comprehensive review

Delcea

Buzea

Vijan

et al. 2023

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Introduction. At the crossroads of heart failure (HF) and systemic inflammation, platelets and lymphocytes are both influenced as well as actively participating in the bidirectional relationship. The platelet to lymphocyte ratio (PLR) could therefore be a marker of severity. This review aimed to assess the role of PLR in HF. Methods. We searched the PubMed (MEDLINE) database using the keywords “platelet”, “thrombocyte”, “lymphocyte”, “heart failure”, “cardiomyopathy”, “implantable cardioverter defibrillator”, “cardiac resynchronization therapy” and “heart transplant”. Results. We identified 320 records. 21 studies were included in this review, with a total of 17,060 patients. PLR was associated with age, HF severity, and comorbidity burden. Most studies reported the predictive power for all-cause mortality. Higher PLR was associated with in-hospital and short-term mortality in univariable analysis, however, it was not consistently an independent predictor for this outcome. PLR > 272.9 associated an adjusted HR of 3.22 (95%CI 1.56 – 5.68, p<0.001) for 30-day fatality. During long-term follow-up from 6 months to 5 years, PLR was an independent predictor of mortality in most studies, with cut-off values ranging from > 150 to > 194.97 and adjusted HR from 1.47 (95%CI 1.06 – 2.03, p=0.019) to 5.65 (95%CI 2.47–12.96, p<0.001). PLR > 173.09 had an adjusted OR 2.89 (95%CI 1.17–7.09, p=0.021) for predicting response to cardiac resynchronization therapy. PLR was not associated with outcomes after cardiac transplant or implantable cardioverter-defibrillator. Conclusion: Increased PLR could be an auxiliary biomarker of severity and survival prognosis in HF patients.

show abstract

Section: Relationship With Coronary Artery Disease and The Risk Of De...mentioning

confidence: 82%

The platelet to lymphocyte ratio in heart failure: a comprehensive review

Delcea

Buzea

Vijan

et al. 2023

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Finally, the cost-effectiveness of the PLR has not been defined. If the diagnostic or predictive properties of PLR are confirmed, it may be a cost-effective solution, at least partially limiting the use of expensive technologies, which may be particularly important in rural areas or less developed countries [52].…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Role of Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis

Pruc,

Peacock,

Rafique

et al. 2023

JCM

View full text Add to dashboard Cite

This study aimed to investigate the potential prognostic role of the platelet-to-lymphocyte (PLR) ratio in patients presenting with suspected acute coronary syndromes (ACS). A systematic search of PubMed Central, Scopus, EMBASE, and the Cochrane Library from conception through 20 August 2023 was conducted. We used odds ratios (OR) as the effect measure with 95% confidence intervals (CIs) for dichotomous data and mean differences (MD) with a 95% CI for continuous data. If I2 was less than 50% or the p value of the Q tests was less than 0.05, a random synthesis analysis was conducted. Otherwise, a fixed pooled meta-analysis was performed. Nineteen studies fulfilled the eligibility criteria and were included in the meta-analysis. PLR was higher in MACE-positive (164.0 ± 68.6) than MACE-negative patients (115.3 ± 36.9; MD = 40.14; 95% CI: 22.76 to 57.52; p < 0.001). Pooled analysis showed that PLR was higher in AMI patients who died (183.3 ± 30.3), compared to survivors (126.2 ± 16.8; MD = 39.07; 95% CI: 13.30 to 64.84; p = 0.003). It was also higher in the ACS vs. control group (168.2 ± 81.1 vs. 131.9 ± 37.7; MD = 39.01; 95% CI: 2.81 to 75.21; p = 0.03), STEMI vs. NSTEMI cohort (165.5 ± 92.7 vs. 159.5 ± 87.8; MD = 5.98; 95% CI: −15.09 to 27.04; p = 0.58), and MI vs. UAP populations (162.4 ± 90.0 vs. 128.2 ± 64.9; MD = 18.28; 95% CI: −8.16 to 44.71; p = 0.18). Overall, our findings confirmed the potential prognostic role of the plate-let-to-lymphocyte (PLR) ratio in patients presenting with suspected acute coronary syndromes (ACS). Its use as a risk stratification tool should be examined prospectively to define its capability for evaluation in cardiovascular patients.

show abstract

“…They could be more prone to developing arrhythmias, particularly atrial fibrillation (Arámbula-Garza et al 2016, Anaszewicz & Budzyński 2017. Platelet-to-lymphocyte ratio (PLR) can be a supplementary biomarker for symptomatic HF, particularly in patients with acute coronary syndrome (ACS) (Intan et al 2022). A study discovered that patients with tetralogy of Fallot (TOF), a congenital abnormality that interferes with proper cardiac blood flow, had a low BMI below the normal limit (Saputri et al 2020).…”

Section: Discussionmentioning

confidence: 99%

Mortality among Heart Failure Patients in the Presence of Cachexia

Andrianto

Karman²,

Mudjanarko³

et al. 2023

FMI

View full text Add to dashboard Cite

Highlights: Around 38.8% of heart failure patients with cachexia died during the 180-1,876-day follow-up period. Cachexia increases the risk of mortality in heart failure patients. Abstract: Despite the fact that obesity has long been recognized as a risk factor for cardiovascular disease, the mortality rate of heart failure (HF) patients with cachexia is still high. Several studies have been conducted to investigate the association between cachexia and mortality in HF patients. However, the research results vary, as do the diagnostic criteria employed to assess cachexia. This meta-analysis aimed to conclusively summarize the association between cachexia and mortality in HF patients. The data were obtained from prospective or retrospective cohort studies with full texts in English or Indonesian and keywords related to "cachexia," "heart failure," and/ or "mortality". Studies that did not assess mortality in HF patients with cachexia and had no full text accessible were omitted. A literature search was conducted through four databases (PubMed, Web of Science, Scopus, and SAGE Journals) using keywords, reference searches, and/ or other methods on April 2022 in accordance with the Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from the selected studies were presented and analyzed using qualitative and quantitative synthesis methods. The Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias in the selected cohort studies. The qualitative synthesis contained nine studies, whereas the quantitative synthesis (meta-analysis) included six studies. Cachexia was found in 16.0% of the 4,697 patients studied. During the 180-1,876-day follow-up period, 33.0% of the patients died, with a mortality rate of 38.8% among the patients with cachexia. The pooled analysis revealed cachexia to be a significant predictor of mortality in HF patients (hazard ratio (HR)=3.84; 95% CI=2.28-6.45; p<0.00001), but with significant heterogeneity (p<0.00001; I2=88%). In conclusion, cachexia worsens HF prognosis.

show abstract

Retrospective Study of the Association Between Platelet-to-Lymphocyte Ratio in Patients with Acute Coronary Syndrome on Admission to a Rural Referral Center in East Java, Indonesia, and the Incidence of New Symptomatic Heart Failure at 6 Months

Cited by 8 publications

References 38 publications

The platelet to lymphocyte ratio in heart failure: a comprehensive review

The platelet to lymphocyte ratio in heart failure: a comprehensive review

The Prognostic Role of Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis

Mortality among Heart Failure Patients in the Presence of Cachexia

Contact Info

Product

Resources

About